Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
28-day open-label safety study of HDM SLIT-tablet in adolescents with HDM allergic rhinitis/rhinoconjunctivitis
2020-000446-34Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- May 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Allergovac Depot in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), house dust mite allergy and 1 more, sponsored by ALK-Abelló. Primary endpoint: Treatment-emergent adverse events. Started May 2020; status: completed.
02
Drugs
Allergovac Depot
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergyasthma
Beyond the preview
Go deeper on 2020-000446-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000446-34.